Zhongguo shi yan xue ye xue za zhi · 2016
[Analysis of Clinical Feature and Curative Efficacy of 30 Patients with T Cell Lymphoblastic Lymphoma].
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Ping, Zhao Wei, Jing Hong-Mei, Hu Kai, Wan Wei, Wang Ji-Jun, Ke Xiao-Yan
Аннотация
OBJECTIVE: To analyze clinical feature and curative efficacy of patients with T cell lymphoblastic lymphoma(T-LBL).
METHODS: The clinical data including clinical features, laboratorial results, survival and prognostic factors from 30 patients with T-LBL were retrospectively analyzed.
RESULTS: Median age of 30 cases was 24.5 years, 25 (83.3%) patients were at high-intermediate and high risk by IPI, extranodal disease was present in 73.3% of the patients, 17(56.7%) patients had bone marrow involvement and 19(63.3%) had mediastinal masses. The overall response rate(ORR) for the whole group was 80.0%, the complete response rate was 36.7%, the 3-5-year overall survival rate was 37.1% and 26.0%, respectively. Compared with NHL-like regimens, ALL-like chemotherapy could improve the survival of patients, the 3-year overall survival rate was 59.1% vs 27.3%. For adult patients, the median overall survival time was 35 months vs 13 months in HSCT group and chemotherapy group, there was a statistically significant difference(P=0.019). ECOG score, IPI score, anemia, the level of LDH and β2-MG, therapy regimens, the short-term efficacy and the level of fibrinogen were the related factors for prognosis.
CONCLUSION: T-LBL is more common in young men, with large mediastinal mass and bone marrow involvement. ALL-like chemotherapy regimens are superior to NHL-like regimens, HSCT can improve the survival and reduce the recurrence of adult patients. Chemotherapy combined with allogeneic DC/CIK immune cell treatment can be used in relapsed patients.
METHODS: The clinical data including clinical features, laboratorial results, survival and prognostic factors from 30 patients with T-LBL were retrospectively analyzed.
RESULTS: Median age of 30 cases was 24.5 years, 25 (83.3%) patients were at high-intermediate and high risk by IPI, extranodal disease was present in 73.3% of the patients, 17(56.7%) patients had bone marrow involvement and 19(63.3%) had mediastinal masses. The overall response rate(ORR) for the whole group was 80.0%, the complete response rate was 36.7%, the 3-5-year overall survival rate was 37.1% and 26.0%, respectively. Compared with NHL-like regimens, ALL-like chemotherapy could improve the survival of patients, the 3-year overall survival rate was 59.1% vs 27.3%. For adult patients, the median overall survival time was 35 months vs 13 months in HSCT group and chemotherapy group, there was a statistically significant difference(P=0.019). ECOG score, IPI score, anemia, the level of LDH and β2-MG, therapy regimens, the short-term efficacy and the level of fibrinogen were the related factors for prognosis.
CONCLUSION: T-LBL is more common in young men, with large mediastinal mass and bone marrow involvement. ALL-like chemotherapy regimens are superior to NHL-like regimens, HSCT can improve the survival and reduce the recurrence of adult patients. Chemotherapy combined with allogeneic DC/CIK immune cell treatment can be used in relapsed patients.